Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29205704 | 0.78 | TET2 (0.30) | TSHRSLC6A2SLC6A4BLMSLC6A3 | |
| SCHEMBL22146032 | 0.77 | TSHR (0.35) | TSHRSLC6A2SLC6A4BLMSLC6A3 | |
| Imidazole SCHEMBL4949319 | 0.76 | ALDH1A1 (0.39) | ALDH1A1 | |
| SCHEMBL6202143 | 0.74 | LMNA (0.32) | GRIK1LMNA | |
| SCHEMBL27642881 | 0.74 | ALDH1A1 (0.32) | TSHRALDH1A1MAPTPTGS1SLC7A5 | |
| SCHEMBL11159731 | 0.72 | — | — | |
| SCHEMBL27963251 | 0.72 | SLC6A2 (0.31) | TSHRSLC6A2SLC6A4BLMSLC6A3 | |
| SCHEMBL9926307 | 0.72 | GRIN2D (0.31) | ALDH1A1MAPTPTGS1 | |
| SCHEMBL27948182 | 0.72 | LMNA (0.32) | KMT2ALMNA | |
| SCHEMBL9181195 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250382264-A1 | HETEROCYCLE-CONTAINING AMINO ACID COMPOUND AND COMPLEX | AICHI STEEL CORPORATION (JP) | 2025-12-18 | — | — | US | disclosed |
| EP-4501909-A1 | HETEROCYCLE-CONTAINING AMINO ACID COMPOUND AND COMPLEX | Aichi Steel Corporation (JP) | 2025-02-05 | — | — | EP | disclosed |
| US-12139482-B2 | Bicyclic pyridone lactams and methods of use thereof | GENENTECH, INC. (US) | 2024-11-12 | — | — | US | disclosed |
| EP-3526219-B1 | BICYCLIC PYRIDONE LACTAMS AND METHODS OF USE THEREOF | HOFFMANN LA ROCHE (CH) | 2021-12-15 | — | — | EP | disclosed |
| US-20210163475-A1 | BICYCLIC PYRIDONE LACTAMS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2021-06-03 | — | — | US | disclosed |
| US-10947226-B2 | Bicyclic pyridone lactams and methods of use thereof | GENENTECH, INC. (US) | 2021-03-16 | — | — | US | disclosed |
| EP-3526219-A1 | BICYCLIC PYRIDONE LACTAMS AND METHODS OF USE THEREOF | H. Hoffnabb-La Roche Ag (CH) | 2019-08-21 | — | — | EP | disclosed |
| US-20190241565-A1 | BICYCLIC PYRIDONE LACTAMS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2019-08-08 | — | — | US | disclosed |
| WO-2018073193-A1 | BICYCLIC PYRIDONE LACTAMS AND METHODS OF USE THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2018-04-26 | — | — | WO | disclosed |
| US-9566577-B1 | Catalytic hydrogenation using complexes of base metals with tridentate ligands | LOS ALAMOS NATIONAL SECURITY, LLC (US) | 2017-02-14 | — | — | US | disclosed |
| US-5849736-A | Isoxazoline and isoxazole fibrinogen receptor antagonists | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1998-12-15 | — | — | US | disclosed |
| EP-0832076-A1 | NOVEL ISOXAZOLINE AND ISOXAZOLE FIBRINOGEN RECEPTOR ANTAGONISTS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1998-04-01 | — | — | EP | disclosed |
| EP-0828737-A1 | ISOXAZOLINE AND ISOXAZOLE DERIVATIVES AS INTEGRIN RECEPTOR ANTAGONISTS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1998-03-18 | — | — | EP | disclosed |
| US-5710159-A | IMIDAZOLIN-2-YLAMINOPROPOXY)ISOXAZOL-5-CARBONYLAMINO-2 -BENZYLOXYCARBONYLAMINOPROPIONIC ACID AS ANTIINFLAMMATORY AGENTS, BONE DEGRADATION, TUMORS, METASTASES AND THROMBOSIS | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1998-01-20 | — | — | US | disclosed |
| WO-1996038426-A1 | NOVEL ISOXAZOLINE AND ISOXAZOLE FIBRINOGEN RECEPTOR ANTAGONISTS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-12-05 | — | — | WO | disclosed |
| WO-1996037492-A1 | ISOXAZOLINE AND ISOXAZOLE DERIVATIVES AS INTEGRIN RECEPTOR ANTAGONISTS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-11-28 | — | — | WO | disclosed |
| US-RE33778-E | 1,3-dithietane-2-carboxylic acid penicillin and cephalosporin derivatives | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1991-12-24 | — | — | US | disclosed |
| US-4414153-A | 1,3-Dithietane-2-carboxylic acid penicillin and cephalosporin derivatives | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1983-11-08 | — | — | US | disclosed |
| US-4198339-A | INTERMEDIATES FOR PENICILLINS AND CEPHALOSPORINS | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1980-04-15 | — | — | US | disclosed |
| US-3946054-A | PERFUMES, TOBACCO, FOOD FLAVORS | INTERNATIONAL FLAVORS & FRAGRANCES INC. (US) | 1976-03-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250382264-A1 | HETEROCYCLE-CONTAINING AMINO ACID COMPOUND AND COMPLEX | NR2C2, NR3C2, NPR1 | TSHR 1311/4885SLC6A2 512/4885SLC6A4 2000/4885 |
| US-20210163475-A1 | BICYCLIC PYRIDONE LACTAMS AND METHODS OF USE THEREOF | CYP3A5, C5, PDXK | TSHR 3026/4885SLC6A2 4738/4885SLC6A4 4525/4885 |
| US-10947226-B2 | Bicyclic pyridone lactams and methods of use thereof | CYP3A5, C5, PDXK | TSHR 3026/4885SLC6A2 4738/4885SLC6A4 4525/4885 |
| US-20190241565-A1 | BICYCLIC PYRIDONE LACTAMS AND METHODS OF USE THEREOF | CYP3A5, C5, PDXK | TSHR 3026/4885SLC6A2 4738/4885SLC6A4 4525/4885 |
| US-12139482-B2 | Bicyclic pyridone lactams and methods of use thereof | CYP3A5, C5, PDXK | TSHR 3026/4885SLC6A2 4738/4885SLC6A4 4525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.